← All Sangamo Therapeutics, INC filings

Sangamo Therapeutics, INC 8-K filings

OTC.Pink
SGMO
Sangamo Therapeutics, INC
8-K: Sangamo Therapeutics Prioritizes Neurology Pipeline, Reports Full Year 2023 Results
Sangamo Therapeutics announced its full year 2023 financial results and highlighted advancements in its neurology pipeline, including promising preclinical data for its novel AAV capsid delivery technology.
OTC.Pink
SGMO
Sangamo Therapeutics, INC
8-K: Sangamo Therapeutics Announces Positive Preliminary Data for Fabry Disease Gene Therapy
Sangamo Therapeutics reported updated positive preliminary clinical data from its Phase 1/2 STAAR study of isaralgagene civaparvovec for Fabry disease, showing sustained enzyme activity and clinical improvements.
OTC.Pink
SGMO
Sangamo Therapeutics, INC
8-K: Sangamo Therapeutics Board Forgoes Executive Bonuses, Implements Retention Program Amid Capital Raise Efforts
Sangamo Therapeutics' board decided against awarding 2023 bonuses to executive officers and established a retention program tied to successful capital raising.